Home
Clinical Trials
Study to Evaluate the Safety ...

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Last Updated: 2021-01-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1113 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-15

Study Completion Date

2020-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899

COVID-19

COMPLETED PHASE3

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

NCT04501952

COVID-19

TERMINATED PHASE3

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

NCT04431453

COVID-19

COMPLETED PHASE2/PHASE3

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351

COVID-19

TERMINATED PHASE3

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

NCT05715528

COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: Remdesivir (RDV), 5 Days

Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.

Group Type EXPERIMENTAL

Remdesivir

Intervention Type DRUG

Administered as an intravenous infusion

Standard of Care

Intervention Type DRUG

Standard of Care Treatment for COVID-19 Infection

Part A: Remdesivir, 10 Days

Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.

Group Type EXPERIMENTAL

Remdesivir

Intervention Type DRUG

Administered as an intravenous infusion

Standard of Care

Intervention Type DRUG

Standard of Care Treatment for COVID-19 Infection

Part A: SOC Therapy

Participants will receive continued standard of care therapy.

Group Type ACTIVE_COMPARATOR

Standard of Care

Intervention Type DRUG

Standard of Care Treatment for COVID-19 Infection

Part B: Extension Treatment, Remdesivir 10 Days

Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.

Group Type EXPERIMENTAL

Remdesivir

Intervention Type DRUG

Administered as an intravenous infusion

Standard of Care

Intervention Type DRUG

Standard of Care Treatment for COVID-19 Infection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remdesivir

Administered as an intravenous infusion

Intervention Type DRUG

Standard of Care

Standard of Care Treatment for COVID-19 Infection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GS-5734™ Veklury®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to provide written informed consent prior to performing study procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and \< 18 years of age) prior to performing study procedures. For participants ≥ 12 and \< 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures
* Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test ≤ 4 days before randomization
* Currently hospitalized and requiring medical care for COVID-19
* Peripheral capillary oxygen saturation (SpO2) \> 94% on room air at screening
* Radiographic evidence of pulmonary infiltrates

Exclusion Criteria

* Participation in any other clinical trial of an experimental treatment for COVID-19
* Concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2
* Requiring mechanical ventilation at screening
* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 X upper limit of normal (ULN)
* Creatinine clearance \< 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age {Cockcroft 1976} and Schwartz Formula for participants \< 18 years of age

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gilead Study Director

Role: STUDY_DIRECTOR

Gilead Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue

Anaheim, California, United States

Site Status

Alta Bates Summit Medical Center

Berkeley, California, United States

Site Status

Mills-Peninsula Medical Center

Burlingame, California, United States

Site Status

Eden Medical Center

Castro Valley, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway

Downey, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave

Fontana, California, United States

Site Status

St Joseph Hospital Eureka

Fortuna, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave.

Harbor City, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave.

Los Angeles, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue

Los Angeles, California, United States

Site Status

Mission Hospital Regional Medical Center

Mission Viejo, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue

Moreno Valley, California, United States

Site Status

El Camino Hospital

Mountain View, California, United States

Site Status

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Site Status

Kaiser Permanente Oakland Medical Center

Oakland, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue

Ontario, California, United States

Site Status

The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange

Orange, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center,13651 Willard Street

Panorama City, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue

Riverside, California, United States

Site Status

Sutter Medical Center Sacramento, One Medical Plaza

Roseville, California, United States

Site Status

Sutter Medical Center Sacramento

Sacramento, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue

San Diego, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd

San Diego, California, United States

Site Status

Kaiser Permanente Oakland Medical Center, 1200 El Camino Real

San Francisco, California, United States

Site Status

California Pacific Medical Center-Infectious Disease Associates Medical Group

San Francisco, California, United States

Site Status

Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd

San Francisco, California, United States

Site Status

Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850

San Jose, California, United States

Site Status

Kaiser Permanente Oakland Medical Center, 2500 Merced St

San Leandro, California, United States

Site Status

Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway

Santa Clara, California, United States

Site Status

Providence St. Johns Medical Center

Santa Monica, California, United States

Site Status

Sutter Santa Rosa Regional Hospital

Santa Rosa, California, United States

Site Status

Stanford Hospital

Stanford, California, United States

Site Status

University of Colorado Denver, University of Colorado Hospital

Aurora, Colorado, United States

Site Status

SCL Health St. Joseph Hospital, 1375 East 19th Ave

Denver, Colorado, United States

Site Status

SCL Health St. Joseph Hospital

Denver, Colorado, United States

Site Status

Rose Medical Center

Denver, Colorado, United States

Site Status

SCL Health St. Joseph Hospital, 200 Exempla Circle.

Lafayette, Colorado, United States

Site Status

Yale University

New Haven, Connecticut, United States

Site Status

Kaiser Permanente Hawaii Moanalua Medical Center

Honolulu, Hawaii, United States

Site Status

Cook County General Hospital

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

IU Health Methodist Hospital

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospitals & Clinics

Iowa City, Iowa, United States

Site Status

Tulane University

New Orleans, Louisiana, United States

Site Status

Maine Medical Center

Portland, Maine, United States

Site Status

Holy Cross Hospital

Silver Spring, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Brigham & Women's Hospital and Harvard Medical School

Boston, Massachusetts, United States

Site Status

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

The University of Michigan Hospitals and Health Systems

Ann Arbor, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Hennepin Healthcare

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Providence St Patrick Hospital and International Heart Institute of MT Foundation

Missoula, Montana, United States

Site Status

Darmouth-Hitchhock Medical Center

Lebanon, New Hampshire, United States

Site Status

Hackensack Medical Center

Hackensack, New Jersey, United States

Site Status

Robert Wood Johnson University Hospital Somerset

Hillsborough, New Jersey, United States

Site Status

Robert Wood Johnson University Hospital Somerset, 1 RWJ Place

New Brunswick, New Jersey, United States

Site Status

Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue

Newark, New Jersey, United States

Site Status

St. Joseph's University Medical Center

Paterson, New Jersey, United States

Site Status

Jamaica Hospital Medical Center

Jamaica, New York, United States

Site Status

Danbury Hospital

Lagrangeville, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status